Corporate
We are delighted to share that ERBC France’s Baugy facility has renewed its accreditation under the Good Laboratory Practice (GLP) framework, issued by Cofrac (Comité Français d’Accréditation) on behalf of the French State.
Following an inspection conducted from November 19 to 21, 2024, our site received a Grade A status, confirming full compliance with GLP principles as defined by Directive 2004/9/CE. This accreditation applies to all studies conducted between November 30, 2022, and November 21, 2024.
Such recognition underscores the commitment of our Baugy team to maintain the highest standards of quality and scientific integrity in every aspect of our work.
The Cofrac certification covers the following OECD-defined study types including Toxicology Studies, Analytical and Clinical Chemistry, and Metabolism Studies
This broad scope ensures robust, traceable, and compliant data for our clients across the pharmaceutical, chemical, and biotech sectors.
Renewal of the GLP accreditation means:
Our clients can continue to rely on ERBC Baugy for precise, compliant, and timely study execution in support of their R&D and regulatory strategies.
Located in central France, the Baugy facility specializes in in vivo, in silico and in vitro studies to support product development. It plays a central role in delivering GLP-compliant services across ERBC’s integrated drug and chemical development platforms.
